{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27","value":"32.74"},{"groupId":"OG001","spread":"7.49","value":"9.04"},{"groupId":"OG002","spread":"16.41","value":"14.61"},{"groupId":"OG003","spread":"17.61","value":"10.02"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"49"}],"units":"Participants"}],"description":"Estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups was made using the log-rank test. Cox proportional hazard regression will be employed for multivariate analysis on time-to-event outcomes.","dispersionType":"Standard Deviation","groups":[{"description":"Oral Revlimid 15mg, Thalidomide 100mg, Dexamethasone 40mg\\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG000","title":"RTD (Cohort 1, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG001","title":"RTD (Cohort 2, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 200mg, Dexamethasone 40mg\\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG002","title":"RTD (Cohort 3, Phase 1)"},{"description":"Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone \\*21 days+ 7 days rest and reevaluation=28 day cycle","id":"OG003","title":"RTD (Cohort 2, Phase 2)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Up to 9 years","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}